Funded by private investors and governments, cancer tests of blood and urine are coming to market.
How much does it cost to bring to market a diagnostic test that’s able to measure cancer without a tissue biopsy?
In the case of Trovagene, almost $100 million.
That’s the cumulative loss, or expense including salaries, R&D, and office space, the money-losing San Diego biotechnology outfit has run up since 1999, when it set out to test for cancer from a cup of urine. Just like recently developed cancer blood tests, the diagnostic the company started offering in May searches for telltale scraps of tumor DNA released by dying cancer cells. The amount of tumor DNA that ends up in urine is a readout, the company says, of whether a tumor has been destroyed or is still growing.
Wall Street analysts expect demand for liquid biopsies to rocket toward $20 billion a year within five years, from about $100 million today.
The idea of such liquid biopsies has leapt to prominence in just the last year. Cancer researchers now expect that the tests will offer a noninvasive way to monitor cancer, find the genetic mutations driving a tumor, or even diagnose it early, before symptoms start. It’s an innovation so big that Wall Street analysts at JP Morgan expect demand for liquid biopsies to rocket toward $20 billion a year within five years, from about $100 million today.
The first DNA blood test for cancer in the United States was commercialized in 2014 by Guardant Health, a venture-backed California company, and tests to spot cancer DNA in blood, urine, or spinal fluid are now in development by a growing number of companies but remain a risky bet for investors.
One pioneering researcher, Dennis Lo, is now tracking more than 20,000 people in Hong Kong to see whether blood screening can catch liver cancer early. Some of his early and ongoing work was paid for by a $1 million grant from the Kadoorie Charitable Foundation, the charity of Hong Kong billionaire Michael Kadoorie, and he later won a $4.25 million award from the Hong Kong government. “It took us about 10 years to convince people to fund us,” he says. Lo says he recently cofounded a company called Cirina to develop blood tests, and he expects initial financing of $12 million from investors.
Investors in the new tests could be disappointed, because while developing a new diagnostic can cost as much as creating a new drug, it’s notoriously hard to make any money off diagnostic tests.
Read more: Bankrolling the 10 Breakthrough Technologies: Liquid Biopsy
The Latest on: Liquid Biopsy
[google_news title=”” keyword=”Liquid Biopsy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Liquid Biopsy
- APCCC 2024: When to Do Tumor Genomic Profiling in Advanced Prostate Cancer and What?on April 26, 2024 at 3:55 pm
Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a session on the management of metastatic CRPC (mCRPC), and a presentation by Dr. Niven Mehra discussing when we should do tumor ...
- Sophia Genetics Announces Syndicate Bio As First Liquid Biopsy Customer In Africaon April 26, 2024 at 1:03 am
Boston, MA and Rolle, Switzerland, April 23, 2024 ndash; SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader i ...
- Medtech’s top executive moves in 2024on April 25, 2024 at 6:28 am
Philips, Illumina, Insulet and Exact Sciences have all gained new CFOs in recent weeks.
- Key Takeaways From Guardant Health Analyst Ratingson April 24, 2024 at 1:01 pm
The 12-month price targets, analyzed by analysts, offer insights with an average target of $35.71, a high estimate of $45.00, and a low estimate of $28.00. Observing a downward trend, the current ...
- FTSE 100 Live 24 April: No record close as index finishes down four points, Lloyds up despite profit slideon April 24, 2024 at 8:38 am
The rejuvenated FTSE 100 index touched a new record today in a session when the focus turned to UK banking stocks. Lloyds Banking Group kicked off the sector’s reporting season by posting a 28% fall ...
- Mercy BioAnalytics to Present Results from a Large Ovarian Cancer Screening Study at the ASCO Annual Meetingon April 24, 2024 at 8:00 am
Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsy for the early detection of cancer, will present data at the 2024 American Society of Clinical Oncology (ASCO) Annual ...
- Company developing early cancer-detection tests to cut 20% of workforceon April 24, 2024 at 7:35 am
Early cancer-detection test maker that raised $254 million earlier this year now says it will cut more than 100 jobs — about 20% of its workforce — as it restructures ...
- Angle inks deal with AstraZenecaon April 24, 2024 at 7:08 am
Liquid biopsy specialist Angle announced a supplier agreement with AstraZeneca on Wednesday to develop and validate a methodology using Angle's existing DNA damage response (DDR) assay for the ...
- Liquid biopsy firm Angle signs new commercial agreement with AstraZenecaon April 24, 2024 at 12:16 am
United Kingdom-based liquid biopsy company Angle (OTCQX:ANPCY) has signed a supplier agreement with the biopharmaceutical company AstraZeneca (NASDAQ:AZN) to tailor the existing Parsortix-based DNA ...
- Non-Invasive Liquid Biopsy Market CAGR of 15.7%, Size, Trends, Growth Status, Share, Research, and Forecast 2024 to 2032on April 16, 2024 at 2:06 pm
Liquid biopsy has emerged as a promising non-invasive technique for detecting and monitoring various types of cancers. Unlike traditional tissue biopsies, which often involve invasive procedures, ...
via Bing News